Sutro Biopharma (STRO) Research & Development (2017 - 2025)

Sutro Biopharma (STRO) has 9 years of Research & Development data on file, last reported at $36.6 million in Q4 2025.

• For the quarter ending Q4 2025, Research & Development fell 48.42% year-over-year to $36.6 million; the trailing twelve-month figure through Dec 2025 stood at $166.4 million (down 33.97% YoY), and the FY2025 full-year result was $166.4 million, down 33.97% from the prior year.
• Research & Development slipped to $36.6 million in Q4 2025, from $39.9 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $71.0 million in Q4 2024 to a low of $22.6 million in Q1 2021.
• A 5-year average of $42.0 million and a median of $39.6 million in 2023 frame the typical range for Research & Development.
• Across the five-year window, Research & Development soared 49.12% in 2024 and sank 48.42% in 2025, its largest moves.
• Tracing STRO's Research & Development over 5 years: stood at $29.9 million in 2021, then surged by 44.13% to $43.1 million in 2022, then climbed by 24.64% to $53.8 million in 2023, then soared by 32.12% to $71.0 million in 2024, then slumped by 48.42% to $36.6 million in 2025.
• Business Quant data shows STRO's Research & Development at $36.6 million in Q4 2025, $39.9 million in Q3 2025, and $38.3 million in Q2 2025.